Month: May 2023

Lyra Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Written by Customer Service on May 12, 2023. Posted in Earnings Releases And Operating Results.

— ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Pre-Surgical Chronic Rhinosinusitis (CRS) on Track to Complete Enrollment, with Data Expected in 1H 2024 — — Data from BEACON Phase 2 Trial of LYR-220 in Post-Surgical CRS Anticipated Q4 2023 — WATERTOWN, Mass., May 12, 2023 (GLOBE NEWSWIRE) — Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), today reported its financial results for the first quarter ended March 31, 2023 and provided a corporate update. “We’ve had a highly productive start to 2023, positioning us for anticipated key data readouts over the next 12 months,” said Maria Palasis, Ph.D., President and CEO of Lyra. “Enrollment is progressing well in...

Bannix Acquisition Corp. Announces Monthly Extension to Complete its Initial Business Combination

Written by Customer Service on May 12, 2023. Posted in Public Companies.

Commences Due Diligence with EVIE AutonomousBannix and EVIE team @ Stoke-on-Trent, UK – May 2023 Bannix and EVIE team @ Stoke-on-Trent, UK – May 2023WEST HOLLYWOOD, Calif., May 12, 2023 (GLOBE NEWSWIRE) — Bannix Acquisition Corp. (“Bannix”) announced today that its board of directors (the “Board”) has decided to extend the date by which Bannix must consummate an initial business combination (the “Deadline Date”) from May 14, 2023 for an additional month, to June 14, 2023. As previously disclosed, at a special meeting of its stockholders held on March 8, 2023, Bannix’ stockholders voted in favor of a proposal to amend Bannix’s Amended and Restated Certificate of Incorporation (as amended, the “Amended Charter”) to provide Bannix with the right to extend the Deadline Date up to 12 times for an additional one month each time (the...

LifeMD, Inc. Reports First Quarter 2023 Results; Record Revenues and Adjusted EBITDA

Written by Customer Service on May 12, 2023. Posted in Public Companies.

Record first quarter 2023 consolidated revenue of $33.1 million, up 14% from the same year-ago period. Record Adjusted EPS of $0.06 per share, up 126% versus the prior year. Record Adjusted EBITDA of $2.0 million, up 126% versus the prior year. Executed debt financing transaction with Avenue Capital, providing up to $40 million of total capital and strengthening LifeMD’s long-term capital position. Re-affirm Full Year 2023 revenue guidance of $140 to $150 million and consolidated Adjusted EBITDA guidance of $12 to $18 million.NEW YORK, May 12, 2023 (GLOBE NEWSWIRE) — LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, reported results for the first quarter ended March 31, 2023. All figure comparisons are to the same year-ago quarter unless otherwise noted. Management will host a conference call today,...

SANUWAVE Announces Q1 2023 Financial Results

Written by Customer Service on May 12, 2023. Posted in Public Companies.

EDEN PRAIRIE, MN, May 12, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – SANUWAVE Health, Inc. (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced 1st quarter 2023 results. For the three-months ended March 31, 2023:Revenues increased 18% to $3.8 million for Q1 2023 versus $3.2 million for the same period last year. This growth falls within the guidance range of 14-20%, provided on the prior conference call. UltraMist® systems sold increased 12% to 28 for Q1 2023, versus 25 systems for the same period last year. UltraMist® applicator cases sold increased 18% to 3,641, versus 3,093 applicator cases for the same period last year. Gross margin as a percentage of revenue decreased for the three months ended March 31, 2023, to 67% from 72% for the same period last year. Operating...

Form 8.3 – [EMIS Group plc – 11 05 2023] – (CGWL)

Written by Customer Service on May 12, 2023. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree EMIS GROUP PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date position held/dealing...

Humacyte First Quarter 2023 Financial Results and Business Update

Written by Customer Service on May 12, 2023. Posted in Earnings Releases And Operating Results.

– Human Acellular Vessel™ (HAV™) granted second RMAT designation by the FDA, for Vascular Trauma – – Completion of enrollment in Phase 3 trial of HAV in Hemodialysis Access in End-Stage Renal Disease Patients – – Conference call and live webcast at 8:00 a.m. ET today – DURHAM, N.C., May 12, 2023 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced financial results for the first quarter ended March 31, 2023, and highlighted recent corporate accomplishments. “We are off to a fast start in 2023 and have moved closer to our planned filing of a Biologics License Application (BLA) for accelerated approval with the U.S. Food and Drug Administration...

Embecta Corp. Reports Second Quarter Fiscal 2023 Financial Results

Written by Customer Service on May 12, 2023. Posted in Earnings Releases And Operating Results.

PARSIPPANY, N.J., May 12, 2023 (GLOBE NEWSWIRE) — Embecta Corp. (“embecta” or the “Company”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, today reported financial results for the three- and six-month periods ended March 31, 2023. “Following our solid first quarter performance, I am pleased to say that our second quarter results have once again exceeded our internal expectations,” said Devdatt (Dev) Kurdikar, Chief Executive Officer of embecta. “We remain focused on executing our three key strategic priorities: strengthening our base business, separating and standing up embecta as an independent company, and investing for growth. During the second quarter, we made progress in each of these areas, as evidenced by our strong revenue performance; exiting additional...

City and 5 more new stores are opening in Akropolis Vilnius

Written by Customer Service on May 12, 2023. Posted in Public Companies.

City Vilnius, Akropolis City Vilnius, AkropolisCity Vilnius, Akropolis City Vilnius, AkropolisOn 12 May, a revamped and expanded store City, which offers modern classics and most famous European brands, opened its doors in the shopping and entertainment centre Akropolis Vilnius. The shopping centre welcomes the upcoming summer also with five other new stores, including the Lacoste brand shop – the only one in Lithuania. The latest City shop that opened in the premises of 561 sq. m in Akropolis Vilnius, offers a wide selection of clothes and accessories of various brands for women and men. Visitors will be able to find clothes of business and smart casual styles and such famous European brands as Marella, Betty Barclay, Joop, Calvin Klein, Gerard Darel, Coccinelle, LiuJo, Ted Baker, Strellson, Roy Robson, they will also be pleasantly...

Vantage Drilling International Reports First Quarter Results for 2023

Written by Customer Service on May 12, 2023. Posted in Earnings Releases And Operating Results.

HOUSTON, May 12, 2023 (GLOBE NEWSWIRE) — Vantage Drilling International (“Vantage” or the “Company”) reported a Net loss attributable to controlling interest of approximately $2.3 million, or $0.17 per diluted share, for the three months ended March 31, 2023, based on the weighted average shares outstanding, as compared to a net loss attributable to controlling interest of $14.9 million, or $1.14 per diluted share, for the three months ended March 31, 2022. As of March 31, 2023, Vantage had approximately $78.8 million in cash, including $8.9 million of restricted cash, compared to $93.3 million in cash, including $19.2 million of restricted cash, at December 31, 2022. At March 31, 2023, Vantage maintained $15.6 million of cash pre-funded by our Managed Services customers to address near-term obligations during the first...

Vital Energy Expands Permian Footprint with Delaware Basin Acquisition

Written by Customer Service on May 12, 2023. Posted in Mergers And Acquisitions.

Accretive transaction strengthens Free Cash Flow outlook and adds ~100 high-value oil-weighted locations TULSA, OK, May 12, 2023 (GLOBE NEWSWIRE) — Vital Energy, Inc. (NYSE: VTLE) (“Vital Energy” or the “Company”) today announced the signing of a definitive joint purchase and sale agreement to acquire the assets of Forge Energy II Delaware, LLC (“Forge”), an EnCap portfolio company, further expanding the Company’s Permian Basin focus and establishing a core operating position in the Delaware Basin. The agreement was signed in partnership with a third party, with the companies jointly agreeing to acquire Forge’s assets in an all-cash transaction for total consideration of $540 million. Vital Energy agreed to acquire 70% of the assets for $378 million and will operate the asset, with the third...

Month: May 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals